Aurinia Pharmaceuticals (AUPH) Net Income (2017 - 2026)

Aurinia Pharmaceuticals (AUPH) has 10 years of Net Income data on file, last reported at $34.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income rose 47.14% year-over-year to $34.4 million; the trailing twelve-month figure through Mar 2026 stood at $298.2 million (up 648.13% YoY), and the FY2025 full-year result was $287.2 million, up 4892.3% from the prior year.
• Net Income for Q1 2026 stood at $34.4 million, down from $210.7 million in the prior quarter.
• Across five years, Net Income topped out at $210.7 million in Q4 2025 and bottomed at -$37.6 million in Q1 2022.
• The 5-year median for Net Income is -$9.0 million (2022), against an average of $8.3 million.
• The widest annual swing landed in 2023, when Net Income slumped 49.59%; it then surged 14168.72% in 2025.
• A 5-year view of Net Income shows it stood at -$26.0 million in 2022, then decreased by 3.26% to -$26.9 million in 2023, then surged by 105.5% to $1.5 million in 2024, then soared by 14168.72% to $210.7 million in 2025, then sank by 83.7% to $34.4 million in 2026.
• The last three Net Income figures came in at $34.4 million (Q1 2026), $210.7 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.

Peer Comparison